Latest European Union News

Sprintex Limited has landed its largest-ever €15.6 million order for ZLD-UP® manure processing systems, marking a pivotal shift from evaluation to commercial deployment across Europe. This multi-year contract sets the stage for substantial revenue growth and a path to profitability in FY26.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

European Metals Holdings has released a Definitive Feasibility Study confirming the Cinovec Lithium Project as a long-life, battery-grade lithium carbonate producer strategically positioned to supply Europe's electric vehicle and energy storage sectors.

TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.

Neuren Pharmaceuticals has secured Health Canada approval to expand its pivotal Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome into Canadian sites, complementing ongoing US enrolment.

EIT RawMaterials has committed an additional €1.5 million to advance the Finnish Vanadium Recovery Project, reinforcing its role in Europe's critical materials supply chain. This marks the third funding round supporting technical innovation and project financing efforts.

Sarytogan Graphite Limited updates investors on its $5 million capital raising, highlighting regulatory approval delays but confirming near-term funding to advance its key graphite project.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Almonty Industries has marked a pivotal milestone by delivering the first ore to the ROM pad at its Sangdong tungsten mine, signaling the start of commercial mining and a strategic shift in global tungsten supply chains.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Osmond Resources has reported strong assay results from its third drill hole at the Orión EU Critical Minerals Project, reinforcing the potential for a globally significant deposit of titanium, zirconium, and rare earth elements. The findings support ongoing development plans targeting EU supply chain needs.